Total Payments
$201,480
2024 Payments
$112,189
Companies
10
Transactions
121
Payment Breakdown by Category
Consulting$183,669 (91.2%)
Travel$9,470 (4.7%)
Research$7,800 (3.9%)
Food & Beverage$540.92 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $183,669 | 90 | 91.2% |
| Travel and Lodging | $9,470 | 11 | 4.7% |
| Unspecified | $7,800 | 7 | 3.9% |
| Food and Beverage | $540.92 | 13 | 0.3% |
Payments by Type
General
$193,680
114 transactions
Research
$7,800
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Travere Therapeutics, Inc. | $80,215 | 66 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $50,974 | 18 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $44,009 | 17 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $11,560 | 11 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $5,350 | 3 | $0 (2024) |
| Novartis Pharma AG | $3,500 | 1 | $0 (2024) |
| Roche Products Limited | $3,220 | 1 | $0 (2021) |
| AstraZeneca UK Limited | $1,470 | 1 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $800.00 | 1 | $0 (2022) |
| Retrophin, Inc. | $381.52 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,189 | 48 | Boehringer Ingelheim International GmbH ($44,009) |
| 2023 | $59,614 | 35 | Travere Therapeutics, Inc. ($43,309) |
| 2022 | $14,596 | 20 | Travere Therapeutics, Inc. ($12,952) |
| 2021 | $5,557 | 7 | Roche Products Limited ($3,220) |
| 2020 | $3,242 | 3 | Alexion Pharmaceuticals, Inc. ($2,000) |
| 2018 | $1,900 | 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,900) |
| 2017 | $4,382 | 7 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($4,000) |
All Payment Transactions
121 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 12/17/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/03/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $220.00 | General |
| 11/26/2024 | Novartis Pharma AG | FOCALIN (Drug) | — | Cash or cash equivalent | $3,500.00 | Research |
| Study: FSGS clinical trials • Category: NEUROSCIENCE | ||||||
| 11/25/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,470.00 | General |
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/13/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,225.00 | General |
| 10/31/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $670.00 | General |
| 10/18/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $8,100.00 | General |
| 10/18/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $267.21 | General |
| 10/17/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 10/15/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 09/17/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 08/19/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $7,087.71 | General |
| 08/19/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 08/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,112.50 | General |
| 08/13/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 07/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| 07/19/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 07/16/2024 | Travere Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 07/11/2024 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $434.14 | General |
| 07/11/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $81.81 | General |
| 07/11/2024 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $32.72 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| FSGS clinical trials | Novartis Pharma AG | $3,500 | 1 |
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ADPKD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,900 | 1 |
| A PHASE 3B, TWO-PART, MULTICENTER, ONE YEAR RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF THE SAFETY, PHARMACOKINETICS, TOLERABILITY, AND EFFICACY OF TOLVAPTAN FOLLOWED BY A TWO YEAR OPEN-LABEL EXTENSION IN CHILDREN AND ADOLESCENT SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,200 | 1 |
| A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-label Extension in Children and Adolescent Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Otsuka Pharmaceutical Development & Commercialization, Inc. | $300.00 | 1 |
| A Pilot Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Efficacy, and Pharmacokinetics of Titrated Oral SAMSCA (Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia | Otsuka Pharmaceutical Development & Commercialization, Inc. | $300.00 | 1 |
| AN EXTENSION FOLLOW-UP TRIAL TO EVALUATE THE LONG-TERM SAFETY OF CHILDREN AND ADOLESCENT SUBJECTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $300.00 | 1 |
| STUDY OF THE SAFETY AND EFFECTIVENESS OF SAMSCA TOLVAPTAN IN CHILDREN AND ADOLESCENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $300.00 | 1 |
About Dr. Howard Trachtman, MD
Dr. Howard Trachtman, MD is a Pediatric Nephrology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942360011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Trachtman, MD has received a total of $201,480 in payments from pharmaceutical and medical device companies, with $112,189 received in 2024. These payments were reported across 121 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($183,669).
Ad
Practice Information
- Specialty Pediatric Nephrology
- Location New York, NY
- Active Since 12/11/2006
- Last Updated 06/18/2013
- Taxonomy Code 2080P0210X
- Entity Type Individual
- NPI Number 1942360011
Products in Payments
- JARDIANCE (Drug) $13,680
- TOLVAPTAN (Drug) $3,800
- SAMSCA (Drug) $3,700
- FOCALIN (Drug) $3,500
- GAZYVA (Biological) $3,220
- Ultomiris (Drug) $2,000
- JYNARQUE (Drug) $1,200
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Nephrology Doctors in New York
Hilary Hotchkiss, M.d, M.D
Pediatric Nephrology — Payments: $150,543
Pediatric Nephrology $150,543
Dr. David Goldsmith, M.d, M.D
Pediatric Nephrology — Payments: $55,762
Pediatric Nephrology $55,762
Dr. Namrata Jain, Md, MD
Pediatric Nephrology — Payments: $1,126
Pediatric Nephrology $1,126
Dr. Laura Malaga Dieguez, M.d. Ph.d, M.D. PH.D
Pediatric Nephrology — Payments: $578.31
Pediatric Nephrology $578.31
Hilda Fernandez, Md, MD
Pediatric Nephrology — Payments: $387.21
Pediatric Nephrology $387.21
Dr. Marissa Lipton, Md, MD
Pediatric Nephrology — Payments: $311.42
Pediatric Nephrology $311.42